Akero Therapeutics Inc AKRO

NAS: AKRO | ISIN: US00973Y1082   30/04/2025
45,61 USD (+5,97%)
(+5,97%)   30/04/2025

7 september 2024 · AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO · Persbericht

21 juni 2024 · AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

17 juni 2024 · Akero Therapeutics, Inc. Investors Reminder: A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. (AKRO) - Contact Kessler Topaz Meltzer & Check, LLP · Persbericht

13 juni 2024 · SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics · Persbericht

8 juni 2024 · AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO · Persbericht

8 juni 2024 · AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

6 juni 2024 · SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics · Persbericht

4 juni 2024 · Akero Therapeutics, Inc. (AKRO): A Securities Fraud Class Action Lawsuit Was Filed Against Akero Therapeutics, Inc. · Persbericht

31 mei 2024 · DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Akero Therapeutics · Persbericht

25 mei 2024 · AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO · Persbericht

24 mei 2024 · AKRO Investors Have Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit · Persbericht

22 mei 2024 · AKRO Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Akero Therapeutics, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit · Persbericht

17 mei 2024 · AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc. · Persbericht

11 mei 2024 · AKERO THERAPEUTICS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Akero Therapeutics, Inc. - AKRO · Persbericht

11 mei 2024 · AKRO Investors: Reminder - Important Deadline in Securities Fraud Class Action Lawsuit Akero Therapeutics, Inc. · Persbericht

1 mei 2024 · NASDAQ: AKRO: Kessler Topaz Meltzer & Check, LLP Notifies Investors of a Securities Class Action Lawsuit Filed Against Akero Therapeutics, Inc. · Persbericht

3 april 2024 · Ademi LLP Investigates Claims of Securities Fraud against Akero Therapeutics, Inc. · Persbericht

14 september 2022 · Dans l'étude HARMONY de phase 2b d'Akero Therapeutics, les doses de 50 mg et 28 mg d'EFX ont atteint la signification statistique sur les critères d'évaluation histologique primaires et secondaires après 24 semaines · Persbericht

13 september 2022 · In Akero Therapeutics’ Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks · Persbericht

22 maart 2021 · Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients · Persbericht

Mijn selecties